As part of Sanofi’s effort to accelerate the development of therapeutics and vaccines that rely on mRNA technology, the company has announced it will acquire its mRNA partner, Lexington-based Translate Bio, for approximately $3.2 billion. “Translate Bio adds an mRNA technology platform and strong capabilities to our research, further advancing our ability to explore the promise of this technology […]

New Jersey based Tonix Pharmaceuticals has announced the start of construction for its planned 45,000 square foot clinical scale manufacturing facility in the New Bedford Business Park. The new facility is expected to house Tonix’s Advanced Development Center (ADC) for accelerated research, development, and analytical capabilities, as well as the production of clinical trial quality […]

Canadian artificial intelligence therapeutics company Deep Genomics has announced the closing of a $180 million Series C financing round with SoftBank Vision Fund 2 leading the financing. Deep Genomics uses AI and machine learning to program and prioritize transformational RNA therapeutics for genetic diseases. The company plans to link its teams in Toronto with the […]

Boston biotech Albireo Pharma has won FDA approval for Bylvay (odevixibat), the first drug approved for the treatment of a rare liver disease called progressive familial intrahepatic cholestasis or PFIC. PFIC is a rare and devastating disorder affecting young children that causes progressive, life-threatening liver disease. In many cases, PFIC leads to cirrhosis and liver […]

Cambridge-based Amylyx Pharmaceuticals has closed a $135 million Series C financing to support the clinical development and potential launch plans for lead product candidate AMX0035, for the potential treatment of ALS, and further research and development in other neurodegenerative diseases. The financing was led by Viking Global Investors with participation from Bain Capital Life Sciences […]

Cambridge-based microbiome therapeutics company Seres Therapeutics has entered into an agreement with Nestlé Health Science to jointly commercialize SER-109, Seres’ investigational oral microbiome therapeutic for recurrent Clostridioides difficile infection (CDI), in the U.S. and Canada. If approved, SER-109 would become the first-ever FDA-approved microbiome therapeutic. Under the terms of the agreement, Nestlé Health Science will utilize its global pharmaceutical business […]